Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Insulet ( (PODD) ) has provided an announcement.
On March 12, 2026, Insulet initiated a voluntary medical device correction in the U.S. for specific lots of its Omnipod 5 Pods after product monitoring identified a manufacturing issue that can cause a tear in internal tubing and lead to under‑delivery of insulin. The company said only about 1.5% of its annual Omnipod 5 pod production is affected, all other Omnipod products remain safe to use, and it continues to manufacture and ship pods without anticipated disruption to product availability or new patient starts.
Insulet disclosed 18 reports of serious adverse events tied to high blood glucose levels, including hospitalizations and cases of diabetic ketoacidosis, but reported no deaths and noted that continuous glucose monitoring systems are not impacted. The company has updated its manufacturing processes and quality controls, expects to incur up to $40 million in related costs in 2026, will exclude these from adjusted results, and is maintaining its previously issued 2026 financial guidance, signaling limited expected impact on its operational outlook.
The most recent analyst rating on (PODD) stock is a Buy with a $338.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.
Spark’s Take on PODD Stock
According to Spark, TipRanks’ AI Analyst, PODD is a Neutral.
The score is driven primarily by strong financial performance (high growth, strong margins, improved balance sheet, and positive free cash flow) and supportive earnings-call guidance/margin expansion plans. These positives are meaningfully tempered by weak technicals (downtrend with negative MACD) and a high P/E with no dividend support, which increases sensitivity to any execution or growth slowdowns.
To see Spark’s full report on PODD stock, click here.
More about Insulet
Insulet Corporation is a Massachusetts‑based medical device company focused on simplifying life for people with diabetes and other conditions through its Omnipod product platform. Its flagship Omnipod 5 Automated Insulin Delivery System offers a tubeless, wearable alternative to traditional insulin delivery that integrates with continuous glucose monitors and can be controlled via smartphone or a dedicated controller.
Average Trading Volume: 943,673
Technical Sentiment Signal: Sell
Current Market Cap: $16.81B
For an in-depth examination of PODD stock, go to TipRanks’ Overview page.